Third-generation thrombolytic drugs

American Journal of Medicine

Volumn 109, Issue 1, 2000, Pages 52-58

  Verstraete, Marc ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; ANTIBODY CONJUGATE; CHIMERIC PROTEIN; FIBRIN; FIBRINOLYTIC AGENT; HEPARIN; LANOTEPLASE; MONTEPLASE; MUTANT PROTEIN; PAMITEPLASE; RETEPLASE; STAPHYLOKINASE; TENECTEPLASE; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG;

ANGIOGRAPHY; ARTERY BLOOD FLOW; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG HALF LIFE; DRUG STABILITY; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; PRIORITY JOURNAL; PROTEIN BINDING; RANDOMIZED CONTROLLED TRIAL; RECANALIZATION; REVIEW;

CLINICAL TRIALS; DRUG EVALUATION; FIBRIN; FIBRINOLYTIC AGENTS; HALF-LIFE; HUMANS; MYOCARDIAL ISCHEMIA; PLASMINOGEN ACTIVATORS; THROMBOLYTIC THERAPY; THROMBOMODULIN;

EID: 0034725801     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(00)00380-6     Document Type: Review

References (62)

1. French J.K., Hyde T.A., Patel H., et al. Survival 12 years after randomization to streptokinase. The influence of thrombolysis in myocardial infarction flow at three to four weeks. Am Coll Cardiol. 34:1999;62-69.
2. The Thrombolysis in Myocardial Infarction (TIMI) Trial Phase I findings . NEJM. 312:1985;932-936.
3. The effects of tissue plasminogen activator, streptokinase, or both on coronary patency, ventricular function, and survival after myocardial infarction. NEJM. 329:1993;1615-1622.
4. Stringer K.A. TIMI grade flow, mortality, and the GUSTO-III trial. Pharmacotherapy. 18:1998;699-705.
5. Gibson C.M., Cannon C.P., Daley W.L., et al. The TIMI count frame. A quantitative method of assessing coronary artery flow. Circulation. 93:1996;879-888.
6. Gibson C.M., Murphy S.A., Rizzo M.J., et al. Relationship between TIMI frame count and clinical outcomes after thrombolytic administration. Circulation. 99:1999;1945-1950.
7. Schröder R., Dissmann R., Bruggemann T., et al. Extent of early ST segment elevation resolution a simple but strong predictor of outcome in patients with acute myocardial infarction . J Am Coll Cardiol. 24:1994;384-391.
8. Schröder R., Wegscheider K., Schröder K., et al. Extent of early ST segment elevation resolution a strong predictor of outcome in patients with acute myocardial infarction and a sensitive measure to compare thrombolytic regimens. A substudy of the International Joint Efficacy Comparison of Thrombolytics (INJECT) Trial . J Am Coll Cardiol. 26:1995;1657-1667.
9. Purcell I.F., Newall N., Farrer M. Change in ST segment elevation 60 minutes after thrombolytic initiation predicts clinical outcome as accurately as later electrocardiographic changes. Heart. 78:1997;465-471.
10. Suzuki S., Saito M., Suzuki N., et al. Thrombolytic properties of a novel modified human tissue-type plasminogen activator (E6010) a bolus injection of E6010 has equivalent potency of lysing young and aged canine coronary thrombi . J Cardiovasc Pharmacol. 17:1991;738-746.
11. Kawai C., Hosoda S., Kimata S., et al. Coronary thrombolysis in acute myocardial infarction of E6010 (Novel modified t-PA) a multicenter, double-blind, dose-finding study . Jpn Pharmacol Ther. 22:1994;3925-3950.
12. Kawai C., Yui Y., Hosoda S., et al. A prospective, randomized, double-blind multicenter trial of single bolus injection of the novel modified t-PA E6010 in the treatment of acute myocardial infarction comparison with native t-PA . J Am Coll Cardiol. 29:1997;1447-1453.
13. Refino C.J., Paoni N.F., Keyt B.A., et al. A variant of t-PA T103N, KHRR296-299 AAAA) that, by bolus, has increased potency and decreased systemic activation of plasminogen. Thromb Haemost. 70:1993;313-319.
14. Fay W.P., Eitzman D.T., Shapiro A.D., et al. Platelets inhibit fibrinolysis in vitro by both plasminogen activator inhibitor-1 dependent and -independent mechanisms. Blood. 83:1994;351-356.
15. Keyt B., Paoni N.F., Refino C.J., et al. A faster-acting and more potent form of tissue plasminogen activator. Proc Natl Acad Sci USA. 91:1994;3670-3674.
16. Collen D., Stassen J.M., Yasuda T., et al. Comparative thrombolytic properties of tissue-type plasminogen activator and of a plasminogen activator inhibitor-1-resistant glycosylation variant, in a combined arterial and venous thrombosis model in the dog. Thromb Haemost. 72:1994;98-104.
17. Cannon C.P., McCabe C.H., Gibson C.M., et al. TNK-tissue plasminogen activator in acute myocardial infarction results of the Thrombolysis in Myocardial Infarction (TIMI) 10A dose-ranging trial . Circulation. 95:1997;351-356.
18. De Marco E, Andreotti F, Van de Greef W, et al. The absence of procoagulant effect after tenecteplase: a comparison with streptokinase and rt-PA. Cardiologia. 1998;43:1209. Abstract.
19. Cannon C.P., Gibson C.M., McCabe C.H., et al. TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction results of the TIMI 10B trial . Circulation. 98:1998;2805-28014.
20. Van de Werf F., Cannon C.P., Luyten A., et al. Safety assessment of single bolus administration of TNK-tPA in acute myocardial infarction the ASSENT-I trial . Am Heart J. 137:1999;786-791.
21. Giugliano RP, Cannon CP, McCabe CH, et al. Lower dose heparin with thrombolysis is associated with lower rates of intracranial hemorrhage: results from TIMI 10B and ASSENT 1. Circulation. 1997;96:535. Abstract.
22. Fox ML, Cannon CP, Berioli S, et al. Rates of serious bleeding events requiring transfusion in AMI patients treated with tenecteplase. Am J Cardiol. 1999;33:353. Abstract.
23. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction the ASSENT-II double-blind randomized trial . Lancet. 354:1999;716-722.
24. Kohnert U., Rudolph R., Verheijen J.H., et al. Biochemical properties of the kringle 2 and protease domains are maintained in the refolded t-PA deletion variant BM 06.022. Prot Engineer. 5:1992;93-100.
25. Stürzebecher J., Neumann U., Kohnert U., et al. Mapping of the catalytic site of CHO-t-PA and the t-PA variant BM 06.022 by synthetic inhibitors and substrates. Prot Sc. 1:1992;1007-1013.
26. Martin U., von Möllendorff E., Akpan W., et al. Dose-ranging study of the novel recombinant plasminogen activator BM 06.022 in healthy volunteers. Clin Pharmacol Ther. 50:1991;429-436.
27. Müller M, Havrer W, Ellbrück D, et al, for the GRECO Study Group. Pharmacokinetics and effects on the hemostatic system of bolus application of a novel recombinant plasminogen activator in AMI patients. Fibrinolysis. 1992;6(suppl 2):26. Abstract.
28. Hajjar K.A. The endothelial cell tissue plasminogen activator receptor. Specific interaction with plasminogen. J Biol Chem. 266:1991;21962-21970.
29. Neuhaus K.L., von Essen R., Vogt A., et al. Dose-finding with a novel recombinant plasminogen activator (BM 06.022) in patients with acute myocardial infarction results of the German recombinant plasminogen activator study . J Am Coll Cardiol. 24:1994;55-60.
30. Tebbe U., von Essen R., Smolarz A., et al. Open, non-controlled dose-finding study with a novel recombinant plasminogen activator (BM 06.022) given as a double bolus in patients with acute myocardial infarction. Am J Cardiol. 72:1993;518-524.
31. Smalling R.W., Bode C., Kalbfleisch J., et al. More rapid, complete and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction. Circulation. 91:1995;2725-2732.
32. Bode C., Smalling R.W., Berg G., et al. Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. Circulation. 94:1996;891-898.
33. Randomized, double-blind comparison to reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT) trial to investigate equivalence . Lancet. 346:1995;329-336.
34. A comparison of reteplase with alteplase for acute myocardial infarction. NEJM. 337:1997;1118-1123.
35. Gurbel P.A., Serebruany V.L., Shustov A.R., et al. Effects of reteplase and alteplase on platelet aggregation and major receptor expression during the first 24 hours of acute myocardial infarction treatment. J Am Coll Cardiol. 31:1998;1466-1473.
36. Lau D., Kuzma G., Wei C.-M., et al. A modified human tissue plasminogen activator with extended half-life in vivo. Bio/Tech. 55:1987;953-958.
37. Larsen G.R., Metzger M., Henson K., et al. Pharmacokinetic and distribution analysis of variant forms of tissue-type plasminogen activator with prolonged clearance in rat. Blood. 73:1989;1842-1850.
38. Eidt J.F., McNatt J., Wydro R.M., et al. Coronary thrombolysis with a variant of human tissue-type plasminogen activator in a canine preparation slightly enhanced thrombolysis and prolonged time to reocclusion . Cor Artery Dis. 2:1991;931-940.
39. Liao W.C., Beierle F.A., Stouffer B.C., et al. Single bolus regimen of lanoteplase (nPA) in acute myocardial infarction pharmacokinetic evaluation from InTIME-1 study . Circulation. 96:(suppl I):1997;I260-I261.
40. den Heijer P., Vermeer F., Ambrosioni E., et al. Evaluation of a weight-adjusted single-bolus plasminogen activator in patients with myocardial infarction. A double-blind, randomized angiographic trial of lanoteplase versus alteplase. Circulation. 98:1998;2117-2125.
41. Kostis JB, Liao W, Beierle FA, et al. Single bolus regimen of lanoteplase (nPA) in acute myocardial infarction: hemostatic evaluation versus TPA in the InTIME study. J Am Coll Cardiol. 1999;33:325. Abstract.
42. Antman EM, Wilcox RG, Giugliano RP, et al, for the InTIME Investigators. Long-term comparison of lanoteplase and alteplase in ST elevation myocardial infarction: 6 month follow-up in InTIME II trial. Circulation. 1999;100:498. Abstract.
43. Katoh M, Suzuki Y, Miyamoto I, et al. Biochemical and pharmacokinetic properties of YM866, a novel fibrinolytic agent. Thromb Haemost. 1991;65:1193. Abstract.
44. Oikawa Y., Kamimura H., Watanabe T., et al. Metabolic fate of YM866, a novel fibrinolytic agent [1] plasma concentration, distribution, metabolism and excretion in rats after single intravenous administration . Xenobio-Metab Dispos. 11:1996;1-10.
45. Kawasaki T., Katoh M., Kaku S., et al. Thrombolytic activity of a novel modified tissue-type plasminogen activator, YM866, in a canine model of coronary artery thrombosis. Jpn J Pharmacol. 63:1993;9-16.
46. Hashimoto K., Oikawa K., Miyamoto I., et al. Phase 1 study of a novel modified t-PA. Jpn J Med Pharm Sci. 36:1996;623-646.
47. Haze K., Kawai C., Hosoda S., et al. Efficacy and safety of intra-coronary administration of YM866 (modified tissue-type plasminogen activator) in patients with acute myocardial infarction. Jpn Pharmacol Ther. 24:1996;2468-2990.
48. Yui Y., Haze K., Kawai C., et al. Randomized, double-blind multicenter trial of YM866 (modified t-PA) by intravenous bolus injection in patients with acute myocardial infarction in comparison with tisokinase (native t-PA). J New Remedies Clin. 45:1996;2175-2221.
49. Lack C.H. Staphylokinase an activator of plasma protease . Nature. 161:1948;559-560.
50. Lewis J.H., Ferguson J.H. A proteolytic enzyme system of the blood. III. Activation of dog serum profibrinolysin by staphylokinase. Am J Physiol. 166:1951;594-603.
51. Collen D., Silence K., Demarsin E., et al. Isolation and characterization of natural and recombinant staphylokinase. Fibrinolysis. 6:1992;203-213.
52. Kowalska-Loth B., Zakrzewski K. The activation by staphylokinase of human plasminogen. Acta Biochim Pol. 22:1975;327-339.
53. Lijnen H.R., Van Hoef B., Collen D. Interaction of staphylokinase with different molecular forms of plasminogen. Eur J Biochem. 211:1993;91-97.
54. Lijnen H.R., Van Hoef B., De Cock F., et al. On the mechanism of fibrin-specific plasminogen activation by staphylokinase. J Biol Chem. 266:1991;11826-11832.
55. Collen D., Schlott B., Engelborghs Y., et al. On the mechanism of the activation of human plasminogen by recombinant staphylokinase. J Biol Chem. 268:1993;8284-8289.
56. Lijnen H.R., Collen D. Staphylokinase, a fibrin-specific bacterial plasminogen. Fibrinolysis. 10:1996;119-126.
57. Vanderschueren S., Barrios L., Kerdsinchai P., et al. A randomized trial of recombinant staphylokinase versus alteplase for coronary artery patency in acute myocardial infarction. Circulation. 92:1995;2044-2049.
58. Sinnaeve P, Janssens S, Van de Werf F. Single bolus administration of polyethylene glycol-derivated cysteine-substitution variants of recombinant staphylokinase in myocardial infarction. Circulation. 1999;100:650. Abstract.
59. Vanderschueren S., Collen D., Van de Werf F. A pilot study on bolus administration of recombinant staphylokinase for coronary artery thrombolysis. Thromb Haemost. 76:1996;541-544.
60. Collen D., Moreau H., Stockx L., et al. Recombinant staphylokinase variants with altered immunoreactivity. II. Thrombolytic properties and antibody induction. Circulation. 94:1996;207-216.
61. Vanderschueren S., Dens J., Kerdsinchai P., et al. A pilot randomized coronary patency trial of double-bolus recombinant staphylokinase versus front-loaded alteplase in acute myocardial infarction. Am Heart J. 134:1997;213-219.
62. Okada K., Lijnen H.R., Moreau H., et al. Procoagulant properties of intravenous staphylokinase versus tissue-type plasminogen activator. Thromb Haemost. 76:1996;857-859.